Welcome to our dedicated page for Synlogic news (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic stock.
Synlogic, Inc. (Nasdaq: SYBX) is a clinical-stage biopharmaceutical company at the forefront of synthetic biology and microbiome research. The company is pioneering the development of Synthetic Biotics™, which are engineered probiotic bacteria designed to perform specific therapeutic functions. These innovative biotherapeutics target a range of metabolic and rare genetic diseases, addressing unmet medical needs.
Using its proprietary Synthetic Biotics™ platform, Synlogic engineers probiotics to correct metabolic dysfunctions linked to various diseases. These therapeutics are primarily delivered orally, acting from the gut microbiome to address systemic issues. The company’s lead programs include treatments for rare genetic metabolic disorders such as phenylketonuria (PKU) and homocystinuria (HCU). Synlogic's pipeline also targets conditions like enteric hyperoxaluria, gout, and cystinuria.
One of Synlogic's flagship projects, labafenogene marselecobac (SYNB1934), is currently in a global, pivotal Phase 3 study for PKU, known as Synpheny-3. Additional candidates, such as SYNB1353 for HCU, are also progressing through clinical stages. The company collaborates with notable partners including Roche for inflammatory bowel disease (IBD) research and Ginkgo Bioworks for synthetic biology advancements.
Synlogic's commitment to innovative medicine is further demonstrated by its recent achievements. In December 2023, the company announced that SYNB1353, a potential treatment for HCU, would be presented at the International Conference on Microbiome Engineering. Additionally, Synlogic secured a $1 million subcontract from the Air Force Research Lab to develop a manufacturing process for a potential live probiotic product, extending a project initiated in 2020.
The company’s approach leverages well-characterized probiotics, such as Escherichia coli Nissle 1917, ensuring consistency, safety, and non-colonizing properties, which simplify oral administration and storage. Synlogic continues to expand its pipeline and research capabilities, driving forward its mission to transform the care of serious diseases through groundbreaking synthetic biology technologies.
Synlogic, Inc. (SYBX) will release its second quarter 2021 financial results on August 12, 2021, prior to market opening. The release will be followed by a conference call at 8:30 am ET, accessible via telephone and webcast. CEO Aoife Brennan will also present at the BTIG Virtual Biotechnology Conference on August 10, 2021. Synlogic focuses on synthetic biology to develop therapeutics for metabolic disorders and is advancing its pipeline in immunology and oncology.
Synlogic, Inc. (Nasdaq: SYBX) has published two significant papers in Nature Metabolism and Communications Biology detailing findings from the first-in-human study of SYNB1618, a Synthetic Biotic™ medicine for treating Phenylketonuria (PKU). The studies indicate SYNB1618 is safe, well-tolerated, and effectively lowers toxic phenylalanine levels in the GI tract of healthy volunteers and PKU patients. Synlogic anticipates proof-of-concept results for SYNB1618 in late 2021 as part of its ongoing Phase 2 clinical trial.
Synlogic, Inc. (Nasdaq: SYBX) announced the initiation of a Phase 1 clinical trial for SYNB1934, a Synthetic Biotic medicine aimed at treating Phenylketonuria (PKU). This new candidate shows a more than 2-fold improvement in phenylalanine (Phe) breakdown compared to its predecessor, SYNB1618. The trial will evaluate the safety, tolerability, and Phe consumption activity of SYNB1934, with results expected by the end of 2021. Synlogic aims to support PKU patients by providing effective treatment options, particularly for those not benefiting from existing therapies.
Synlogic, Inc. (SYBX) has entered a research collaboration agreement with Roche to develop a novel Synthetic Biotic medicine for inflammatory bowel disease (IBD). This partnership aims to address an undisclosed target in IBD, reflecting Synlogic's commitment to innovative treatments. Roche will have an exclusive option for further development and commercialization following the research period. Synlogic's pipeline includes treatments for metabolic disorders, emphasizing the company's focus on addressing unmet patient needs in inflammation.
Synlogic, a clinical-stage company, presented at the SEED conference on SYNB8802 and SYNB1934, investigational Synthetic Biotic medicines targeting Enteric Hyperoxaluria and Phenylketonuria (PKU), respectively. SYNB1934 shows over a 2-fold improvement in metabolizing phenylalanine compared to SYNB1618, while SYNB8802 demonstrates strain activity throughout the GI tract. Both treatments aim to address unmet medical needs, as no approved options currently exist for these conditions. The presentations highlight Synlogic's commitment to using synthetic biology for innovative therapies.
Synlogic, Inc. (Nasdaq: SYBX) has announced its 2021 Annual General Meeting of Stockholders will occur on June 10, 2021, at 9:00 am ET, via virtual format.
Stockholders of record as of April 13, 2021, can access the meeting through this link starting at 8:45 am ET. Synlogic encourages stockholders to vote and submit proxies beforehand. The company focuses on developing Synthetic Biotic medicines for metabolic disorders and has a proprietary pipeline targeting additional diseases.
Synlogic, Inc. (Nasdaq: SYBX) announced that President and CEO Aoife Brennan will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 1:30 pm. This virtual event will feature a Fireside Chat, and a live webcast will be accessible through the company's website, with an archived version available for 30 days post-event. Synlogic leverages synthetic biology to develop innovative therapeutics for metabolic disorders and is expanding its portfolio in immunology and oncology.
On May 23, 2021, Synlogic, Inc. (SYBX) presented data on its Synthetic Biotic medicines aimed at treating inflammatory bowel disease (IBD) during Digestive Disease Week. The presentation, delivered by Mylene Perreault, showcased an investigational program focusing on a novel IL-22-secreting Synthetic Biotic. Synlogic aims to leverage synthetic biology to innovate treatments for various diseases, with a proprietary pipeline also targeting metabolic disorders like Phenylketonuria. The event was held virtually from May 21-23, 2021.
Synlogic, Inc. (Nasdaq: SYBX) reported Q1 2021 results, highlighting its progress in developing Synthetic Biotic medicines. The company remains on track with its SynPheny-1 Phase 2 trial for SYNB1618, targeting Phenylketonuria (PKU), and anticipates data in H2 2021. SYNB8802, aimed at Enteric Hyperoxaluria, demonstrated a 28.6% reduction in urinary oxalate in early studies. Synlogic completed a $32.6 million public offering, bringing cash reserves to $127 million. The firm expects to sustain operations through mid-2023 with its current cash flow and strategic partnerships.
Synlogic, Inc. (SYBX), a clinical-stage company focusing on synthetic biology, will announce its first quarter 2021 financial results on May 13, 2021, prior to market opening. A conference call will follow at 8:30 am ET to discuss these results and provide a corporate update. Participants can join via a provided dial-in number or through a webcast. The company specializes in developing Synthetic Biotic therapeutics for metabolic disorders.
FAQ
What is the current stock price of Synlogic (SYBX)?
What is the market cap of Synlogic (SYBX)?
What does Synlogic, Inc. specialize in?
What are Synthetic Biotics™?
What is Synlogic’s lead program?
What diseases are covered by Synlogic's pipeline?
How does Synlogic deliver its Synthetic Biotics™?
Who are Synlogic's research partners?
What recent achievements has Synlogic announced?
What makes Synlogic's probiotics unique?
What is SYNB1353 aimed at treating?
Where can I find more information about Synlogic?
